Professional Insertion Helps Reduce Member Error and Risk
Eversense’s unique fully inserted subcutaneous sensor is designed to be inserted and removed by a healthcare provider in a clinical setting. This can reduce the risk of injuries, site infections and other adverse events associated with patient self-removal and insertion in the home.
~ 5 mm Incision in upper arm
under local anesthetic
Sensor inserted with custom insertion tool
Close Insertion Site
Steri-StripsTM to close
“The study had demonstrated the safety of an implanted CGM system in a controlled multicenter clinical trial and did not expose any unanticipated risks.”*
No Device-Related Serious Adverse Events (SAE) Across Three Major Studies2-4
In three pivotal studies (PRECISE, PRECISE II, and PRECISION), the Eversense CGM System demonstrated an excellent safety profile, as measured by the incidence of adverse events tied to the device or sensor insertion/removal procedures, during continuous use for up to 90 days.5
To learn more on how a professionally-inserted CGM system can reduce risk to members, contact us to get a copy of our device safety paper.
1 Christiansen MP, et al. PRECISION. Diabetes Technology & Therapeutics, Volume 21, Number 5, 2019. 2 Kropff J, Choudhary P, Neupane S, et al. PRECISE. Diabetes Care. 2017;40(1):63-68. 3 Christiansen MP, Klaff LJ, Brazg R, et al. PRECISE II. Diabetes Technol Ther. 2018;20(3):197-206. 4 Christiansen MP, et al. PRECISION. Diabetes Technology & Therapeutics, Volume 21, Number 5, 2019. 5 PRECISE II Pivotal Trial of A Long Term Implantable CGM System: 90 Days of Sustained Accuracy and Strong Safety Profile. 2017.